Amulet IDE Trial Supports Abbott’s New LAA Closure Device
Results of the trial showed Amplatzer Amulet was superior to Boston Scientific’s Watchman for left-atrial appendage closure and noninferior for safety and effectiveness.
You may also be interested in...
This edition of Medtech Insight’s regular round-up of heart-tech news covers some highlights of this years’ Transcatheter Cardiovascular Therapeutics (TCT) meeting in September, including the latest trials of Abbott's Amulet left-atrial appendage closure device and Medtronic's Intrepid transcatheter mitral valve replacement.
June, July and August brought a number of important new approvals and trial announcements from the major cardiac device companies. Here are some of the highlights you might have missed during the summer.
Amplatzer Amulet is a percutaneous transcatheter device designed to prevent thrombus embolization from the left-atrial appendage in people with nonvalvular atrial fibrillation.